Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Cell Therapy Transplant Canada

doi:10.1016/S2352-3026(19)30220-0

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Cell Therapy Transplant Canada

Pharmacology, Toxicology and Pharmaceutics

科研成果: 期刊稿件 › 文章 › 同行评审

70 引用（Scopus）

源语言	英语
页（从-至）	e100-e111
期刊	The Lancet Haematology
卷	7
期	2
DOI	https://doi.org/10.1016/S2352-3026(19)30220-0
出版状态	已出版 - 2月 2020

!!!ASJC Scopus Subject Areas

血液学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/S2352-3026(19)30220-0

其它文件与链接

指纹

探究 'Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial' 的科研主题。它们共同构成独一无二的指纹。

引用此

Cell Therapy Transplant Canada (2020). Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology, 7(2), e100-e111. https://doi.org/10.1016/S2352-3026(19)30220-0

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. / Cell Therapy Transplant Canada.
在: The Lancet Haematology, 卷 7, 号码 2, 02.2020, 页码 e100-e111.

科研成果: 期刊稿件 › 文章 › 同行评审

Cell Therapy Transplant Canada 2020, 'Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial', The Lancet Haematology, 卷 7, 号码 2, 页码 e100-e111. https://doi.org/10.1016/S2352-3026(19)30220-0

Cell Therapy Transplant Canada. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology. 2020 2月;7(2):e100-e111. doi: 10.1016/S2352-3026(19)30220-0

Cell Therapy Transplant Canada. / Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors : final analysis of a randomised, open-label, multicentre, phase 3 trial. 在: The Lancet Haematology. 2020 ; 卷 7, 号码 2. 页码 e100-e111.

@article{852a15bdea7347cf873979cb28946266,

title = "Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial",

author = "{Cell Therapy Transplant Canada} and Irwin Walker and Tony Panzarella and Stephen Couban and Felix Couture and Gerald Devins and Mohamed Elemary and Genevi{\`e}ve Gallagher and Holly Kerr and John Kuruvilla and Lee, {Stephanie J.} and John Moore and Thomas Nevill and Gizelle Popradi and Jean Roy and Schultz, {Kirk R.} and David Szwajcer and Cynthia Toze and Ronan Foley",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = feb,

doi = "10.1016/S2352-3026(19)30220-0",

language = "English",

volume = "7",

pages = "e100--e111",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors

T2 - final analysis of a randomised, open-label, multicentre, phase 3 trial

AU - Cell Therapy Transplant Canada

AU - Walker, Irwin

AU - Panzarella, Tony

AU - Couban, Stephen

AU - Couture, Felix

AU - Devins, Gerald

AU - Elemary, Mohamed

AU - Gallagher, Geneviève

AU - Kerr, Holly

AU - Kuruvilla, John

AU - Lee, Stephanie J.

AU - Moore, John

AU - Nevill, Thomas

AU - Popradi, Gizelle

AU - Roy, Jean

AU - Schultz, Kirk R.

AU - Szwajcer, David

AU - Toze, Cynthia

AU - Foley, Ronan

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85078261688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078261688&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(19)30220-0

DO - 10.1016/S2352-3026(19)30220-0

M3 - Article

C2 - 31958417

AN - SCOPUS:85078261688

SN - 2352-3026

VL - 7

SP - e100-e111

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 2

ER -